6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality

      research-article

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objectives

          To examine the incidence, predictors and outcomes associated with severe gastrointestinal (GI) disease in a large inception SSc cohort.

          Methods

          SSc subjects with <2 years of disease duration were identified from two multicentre cohorts. Severe GI disease was defined as: malabsorption, hyperalimentation, pseudo-obstruction and/or ⩾10% weight loss in association with the use of antibiotics for bacterial overgrowth or oesophageal stricture. Kaplan–Meier, multivariate logistic regression and Cox proportional hazard analyses were performed to determine the cumulative incidence rate, independent clinical correlates and mortality rate associated with severe GI disease. A longitudinal mixed model was used to assess the impact of severe GI disease on the Short Form Health Survey.

          Results

          In this inception SSc cohort, the probability of developing severe GI disease was estimated at 9.1% at 2 years and 16.0% at 4 years. In multivariate analysis, severe GI disease was associated with inflammatory myositis (odds ratio 4.68, 95% CI 1.65, 13.24), telangiectasias (odds ratio 2.45, 95% CI 1.19, 5.04) and modified Rodnan skin score (odds ratio 1.03, 95% CI 1.01, 1.07). Severe GI disease was associated with a >2-fold increase in the risk of death (hazard ratio 2.27, 95% CI 1.27, 4.09) and worse health-related quality of life [Short Form Health Survey physical (β = −2.37, P = 0.02) and mental (β = −2.86, P = 0.01) component summary scores].

          Conclusion

          Severe GI disease is common in early SSc and is associated with significant morbidity and increased mortality. More research is needed to understand, prevent and mitigate severe GI disease in SSc.

          Related collections

          Most cited references32

          • Record: found
          • Abstract: found
          • Article: not found

          Early Mortality in a Multinational Systemic Sclerosis Inception Cohort.

          To determine mortality and causes of death in a multinational inception cohort of subjects with systemic sclerosis (SSc).
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Gastrointestinal motility disorders in scleroderma.

            R Sjögren (1994)
            After the skin, the gastrointestinal tract is the second most common target of systemic sclerosis. The major clinical manifestations include gastroesophageal reflux, small bowel bacterial overgrowth, malnutrition, and intestinal pseudoobstruction. Treatment is symptomatic and supportive. Gastroesophageal reflux can usually be adequately managed with prokinetic drugs, omeprazole, and judicious use of antireflux surgery. If Barrett's esophagus is present, periodic endoscopic monitoring for development of dysplastic changes or adenocarcinoma is indicated. Bacterial overgrowth usually responds to rotating antibiotics and prokinetic drugs. Malnutrition and intestinal pseudoobstruction remain the major problems and often home total parenteral nutrition is required. Intestinal pseudoobstruction occurs in two phases: an early, neuropathic phase may respond to prokinetic drugs (metoclopramide, cisapride, octreotide, and erythromycin) and dietary modification (low-residue diets, vitamin supplementation). In the late myopathic phase, therapy is usually ineffective. Treatment consists of nutritional support. Careful manometric and radiographic localization of affected segments of stomach and small and large intestines may allow judicious surgical resection or venting procedures to reduce symptoms in this unfortunate group of patients.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Impaired quality of life in systemic sclerosis and patient perception of the disease: A large international survey

                Bookmark

                Author and article information

                Journal
                Rheumatology (Oxford)
                Rheumatology (Oxford)
                brheum
                Rheumatology (Oxford, England)
                Oxford University Press
                1462-0324
                1462-0332
                April 2019
                04 December 2018
                04 December 2019
                : 58
                : 4
                : 636-644
                Affiliations
                [1 ]Division of Rheumatology, Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada
                [2 ]Department of Medicine, McGill University, Montreal, Quebec, Canada
                [3 ]Division of Rheumatology, Jewish General Hospital, Montreal, Quebec, Canada
                [4 ]Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada
                [5 ]Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia
                [6 ]Discipline of Medicine, University of Adelaide, Adelaide, South Australia
                [7 ]Department of Rheumatology, St Vincent’s Hospital, Melbourne, Victoria, Australia
                [8 ]Department of Medicine, University of Melbourne at St Vincent’s Hospital, Melbourne, Victoria, Australia
                Author notes
                Correspondence to: Murray Baron, Division of Rheumatology, Jewish General Hospital, A.725-3755 chemin de la Côte-Sainte-Catherine, Montreal, Quebec H3T 1E2, Canada. E-mail: mbaron@ 123456jgh.mcgill.ca
                Author information
                http://orcid.org/0000-0003-3683-8713
                Article
                PMC6434374 PMC6434374 6434374 key350
                10.1093/rheumatology/key350
                6434374
                30517716
                ad480db5-24e7-4b2e-ab90-1b33c95f1a23
                © The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com

                This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

                History
                : 10 June 2018
                : 23 September 2018
                Page count
                Pages: 9
                Funding
                Funded by: Canadian Scleroderma Research Group
                Funded by: CSRG
                Funded by: Canadian Institutes of Health Research 10.13039/501100000024
                Award ID: #FRN 83518
                Funded by: CIHR 10.13039/501100000024
                Funded by: Scleroderma Society of Canada
                Funded by: Scleroderma Society of Ontario
                Funded by: Scleroderma Society of Saskatchewan
                Funded by: Sclérodermie Québec
                Funded by: Cure Scleroderma Foundation
                Funded by: INOVA Diagnostics Inc
                Funded by: Pfizer 10.13039/100004319
                Funded by: Actelion pharmaceuticals
                Funded by: Fonds de la recherche du Québec – Santé
                Funded by: FRQS 10.13039/501100000156
                Funded by: Australian Scleroderma Interest Group (ASIG)
                Funded by: Scleroderma Australia
                Funded by: Scleroderma Victoria
                Funded by: Arthritis Australia 10.13039/501100000940
                Funded by: Actelion Australia
                Funded by: MOVE 10.13039/501100011578
                Funded by: The Australian Rheumatology Association
                Funded by: The Scleroderma Clinical Trials Consortium
                Funded by: St Vincent’s Hospital Research Endowment Fund
                Funded by: Bayer 10.13039/100004326
                Funded by: CSL Biotherapies
                Funded by: GlaxoSmithKline Australia 10.13039/501100001203
                Funded by: Roche 10.13039/100004337
                Funded by: Hôpital Maisonneuve Rosemont Department of Medicine Foundation
                Funded by: Fonds de la recherche du Québec – Santé
                Funded by: FRQS 10.13039/501100000156
                Funded by: National Health and Medical Research Council of Australia
                Award ID: APP 1126370
                Categories
                Clinical Science

                gastrointestinal manifestations,mortality,systemic sclerosis,health-related quality of life,scleroderma

                Comments

                Comment on this article